The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2016 | Key studies on multiple myeloma presented at ASH 2016
Paul Richardson, MD of Dana-Farber Cancer Institute, Boston, MA discusses key studies in multiple myeloma (MM) presented at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA. Prof. Richardson discusses data presented on pembrolizumab combined with IMiDs, as well as data on venetoclax combined with bortezomib, and marizomib and pomalidomide. He also talks about the selinexor compound, which represents a novel class of drug and the combination strategies with bortezomib in the STOMP trial (NCT02343042).
